Resources for Patients and Caregivers
A type of bipolar disorder characterized by depressive and hypomanic episodes.
It involves at least one depressive episode lasting at least two weeks and at least one hypomanic episode lasting at least four days.
Depressive symptoms include sadness or hopelessness. Hypomanic symptoms include a persistently elevated or irritable mood.
Treatment includes counseling and medications, such as mood stabilizers.
Wiki Number: 09-Bipolar II
Diagnosis: One or more long sessions of depression, some hypo(lower)mania, but no full manic session
Symptoms: May be more chronic and recurring in the depressive phase than Bipolar I.
Progression: May be a high risk of suicide. 25-50% of Bipolar II patients make at least one suicide attempt.
Medications: Can be modified by several medications.
Youtube Video: Bipolar 1 or Bipolar 2 Disorder – Which is Worse?
Amazon or Library Book: Bipolar II Disorder Workbook
Click the book to link or order from Amazon.
Support Group: dsballiance.org; 800-326-3632
(Depression and Bipolar Support Alliance)
Contact your local Social Security office for possible Disability Benefits through their Disability Determination Services,
Resources for Physicians, Counselors and Researchers
4 CURRENT ARTICLES
The world-wide medical research
reports chosen for each diagnosis
Clicking each title opens the
PubMed article’s summary-abstract.
- A quality assessment of clinical practice guidelines with recommendations for family involvement in the care of individuals diagnosed with schizophrenia, bipolar mood disorder, and major depressive disorder: Critical appraisal utilizing AGREE IIby Raziye Dehbozorgi on January 23, 2023
CONCLUSION: The applicability of the guidelines needs to be improved in order to improve their relevance and clinical utilization. As individuals with chronic mental illnesses progress through their disease course, families and health care providers play a crucial role in helping them. The analysis of research knowledge on effective rehabilitation techniques, including the involvement of families in treatment, can be enhanced by using well-developed and appropriate methods.
- Does treatment with autophagy-enhancers and/or ROS-scavengers alleviate behavioral and neurochemical consequences of low-dose rotenone-induced mild mitochondrial dysfunction in mice?by O Damri on January 23, 2023
Bipolar-disorder's pathophysiology and the mechanism by which medications exert their beneficial effect is yet unknown, but others' and our data implicate patients' brain mitochondrial-dysfunction and its amendment by mood-stabilizers. We recently designed a novel mouse bipolar-disorder-like model using chronic administration of a low-dose of the oxidative-phosphorylation complex I inhibitor, rotenone. Four and eight weeks rotenone treatment induced manic- and depressive-like behavior,...
- Korean Validation of the Short Version of the TEMPS-A (Temperament Evaluation of Memphis, Pisa, Paris, and San Diego Autoquestionnaire) in Patients with Mood Disordersby Sunho Choi on January 21, 2023
CONCLUSIONS: Overall, the results show that the TEMPS-A-SV is a reliable and valid measurement that can be used for estimating Koreans' affective temperaments. However, more research is required on affective temperaments and associated characteristics in people with mood disorders.
- Divergent Directionality of Immune Cell-Specific Protein Expression between Bipolar Lithium Responders and Non-Responders Revealed by Enhanced Flow Cytometryby Keming Gao on January 21, 2023
Background and Objectives: There is no biomarker to predict lithium response. This study used CellPrint™ enhanced flow cytometry to study 28 proteins representing a spectrum of cellular pathways in monocytes and CD4^(+) lymphocytes before and after lithium treatment in patients with bipolar disorder (BD). Materials and Methods: Symptomatic patients with BD type I or II received lithium (serum level ≥ 0.6 mEq/L) for 16 weeks. Patients were assessed with standard rating scales and divided into two...